STANDARD ARTICLE

Long-term incidence and risk of noncardiovascular and all-cause mortality in apparently healthy cats and cats with preclinical hypertrophic cardiomyopathy

Philip R. Fox[1] | Bruce W. Keene[2] | Kenneth Lamb[3] | Karsten E. Schober[4] |
Valérie Chetboul[5] | Virginia Luis Fuentes[6] | Jessie Rose Payne[7] |
Gerhard Wess[8] | Daniel F. Hogan[9] | Jonathan A. Abbott[10] |
Jens Häggström[11] | Geoffrey Culshaw[12] | Deborah Fine-Ferreira[13] |
Etienne Cote[14] | Emilie Trehiou-Sechi[15] | Alison A. Motsinger-Reif[16] |
Reid K. Nakamura[17] | Manreet Singh[18] | Wendy A. Ware[19] | Sabine C. Riesen[20] |
Michele Borgarelli[21] | John E. Rush[22] | Andrea Vollmar[23] | Michael B. Lesser[24] |
Nicole Van Israel[25] | Pamela Ming-Show Lee[26] | Barret Bulmer[27] |
Roberto Santilli[28] | Maribeth J. Bossbaly[29] | Nadine Quick[30] | Claudio Bussadori[31] |
Janice Bright[32] | Amara H. Estrada[33] | Dan G. Ohad[34] |
Maria Josefa Fernández del Palacio[35] | Jennifer Lunney Brayley[36] |
Denise S. Schwartz[37] | Sonya G. Gordon[38] | SeungWoo Jung[39] |
Christina M. Bove[40] | Paola G. Brambilla[41] | N. Sydney Moïse[42] |
Christopher Stauthammer[43] | Cecilia Quintavalla[44] | Ferenc Manczur[45] |
Rebecca L. Stepien[46] | Carmel Mooney[47] | Yong-Wei Hung[48] | Remo Lobetti[49] |
Alice Tamborini[50] | Mark A. Oyama[51] | Andrey Komolov[52] | Yoko Fujii[53] |
Romain Pariaut[54] | Masami Uechi[55] | Victoria Yukie Tachika Ohara[56]

[1]Animal Medical Center, New York, New York, U.S.A.

[2]College of Veterinary Medicine, North Carolina State University, Department of Clinical Sciences, Raleigh, North Carolina, U.S.A.

[3]Lamb Consulting, Minneapolis, Minnesota, U.S.A.

[4]Department of Veterinary Clinical Sciences, The Ohio State University, Columbus, Ohio, U.S.A.

[5]Alfort Cardiology Unit, École Nationale Vétérinaire d'Alfort, Maisons-Alfort Cedex, France

[6]Department of Veterinary Clinical Sciences and Services, Royal Veterinary College, Hatfield, United Kingdom

[7]Highcroft Veterinary Referrals, Bristol, United Kingdom

[8]Clinic of Small Animal Medicine, Ludwig-Maximillians University, Munich, Germany

[9]Department of Veterinary Clinical Sciences, Purdue University, West Lafayette, Indiana, U.S.A.

[10]Department of Small Animal Clinical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Blacksburg, Virginia, U.S.A.

[11]Department of Clinical Sciences, Swedish University of Agricultural Sciences, Uppsala, Sweden

[12]Division of Veterinary Clinical Sciences, R(D)SVS Hospital for Small Animals Easter Bush Veterinary Centre, The University of Edinburgh, Midlothian, United Kingdom

[13]Ali'i Veterinary Hospital, Kailua-Kona, Hawaii, U.S.A.

[14]Atlantic Veterinary College, Univertisy of PEI—Department of Companion Animals, Charlottetown, Prince Edward Island, Canada

[15]École Nationale Vétérinaire d'Alfort, Cardiology Unit of Alfort—Université Paris-Est, Maisons-Alfort, France

[16]Department of Statistics, North Carolina State University, Raleigh, North Carolina, U.S.A.

[17]Advanced Veterinary Care Center—Cardiology, Lawndale, California, U.S.A.

[18]Veterinary Cardiac Referrals—Cardiology, Sydney, New South Wales, Australia

[19]Department of Veterinary Clinical Sciences, Iowa State University, Ames, Iowa, U.S.A.

[20]Kardiovet, Burgdorf, Switzerland

[21]Department of Small Animal Clinical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Blacksburg, Virginia, U.S.A.

[22]Department of Clinical Sciences, Tufts University Cummings School of Veterinary Medicine, North Grafton, Massachusetts, U.S.A.

[23]Small Animal Clinic, Wissen and Bonn, Germany

[24]Advanced Veterinary Care Center, Lawndale, California, U.S.A.

[25]Animal CardioPulmonary Consultancy, Masta, Belgium

[26]Department of Veterinary Clinical Sciences, Washington State University, Pullman, Washington, U.S.A.

[27]Tufts Veterinary Emergency Treatment & Specialties, Walpole, Massachusetts, U.S.A.

[28]Department of Cardiology, Clinica Veterinaria Malpensa, Varese, Italy

[29]Veterinary Specialty & Emergency Center, Levittown, Pennsylvania, U.S.A.

[30]Ludwig-Maximilians-University Munich, Clinic of Small Animal Medicine, Munich, Germany

[31]Department of Cardiology, Clinica Veterinaria Gran Sasso, Milano, Italy

[32]Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado, U.S.A.

[33]Department of Small Animal Clinical Sciences, University of Florida College of Veterinary Medicine, Gainesville, Florida, U.S.A.

[34]The Koret School of Veterinary Medicine, The Hebrew University of Jerusalem, Rehovot, Israel

[35]Departmento de Medicina y Cirugía Animal, Universidad de Murcia, Murcia, Spain

[36]Veterinary Medical Specialists of Houston, Houston, Texas, U.S.A.

[37]School of Veterinary Medicine, University of Sao Paulo, Sao Paulo, Brazil

[38]Department of Small Animal Clinical Sciences, Texas A&M University, College Station, Texas, U.S.A.

[39]Department of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, Alabama, U.S.A.

[40]Department of Clinical Sciences, Colorado State University, Fort Collins, Colorado, U.S.A.

[41]Department of Veterinary Medicine, University of Milan, Milan, Italy

[42]Department of Clinical Sciences, Cornell University, Ithaca, New York, U.S.A.

[43]Department of Veterinary Clinical Sciences, University of Minnesota, St. Paul, Minnesota, U.S.A.

[44]Department of Veterinary Sciences, University of Parma, Parma, Italy

[45]Department of Internal Medicine, University of Veterinary Medicine, Budapest, Hungary

[46]Department of Medical Sciences, University of Wisconsin Madison School of Veterinary Medicine, Madison, Wisconsin, U.S.A.

[47]University College Dublin Veterinary Hospital, University College Dublin, Dublin, Ireland

[48]Cardiospecial Veterinary Hospital, Taipei, Taiwan

[49]Bryanston Veterinary Hospital, Bryanston, South Africa

[50]Department of Small Animal Medicine, University College Veterinary Hospital, University College Dublin, Dublin, Ireland

[51]Department of Clinical Studies, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.

[52]Veterinary Clinic Beliy Clyk, Moscow, Russia

[53]Laboratory of Surgery 1, Azabu University, Sagamihara, Japan

[54]Department of Veterinary Clinical Sciences, Cornell University, Ithaca, New York, U.S.A.

[55]Jasmine Animal Cardiovascular Center, Yokohama, Japan

[56]Department of Medicine, Surgery and Zootechnics for Small Species, Universidad Nacional Autónoma de México, Mexico City, Mexico

Correspondence
Philip R. Fox, Animal Medical Center, 510 East 62nd Street, New York, NY, U.S.A.
Email: philip.fox@amcny.org

Abstract

Background: Epidemiologic knowledge regarding noncardiovascular and all-cause mortality in apparently healthy cats (AH) and cats with preclinical hypertrophic cardiomyopathy (pHCM) is limited, hindering development of evidence-based healthcare guidelines.

Objectives: To characterize/compare incidence rates, risk, and survival associated with noncardiovascular and all-cause mortality in AH and pHCM cats.

Animals: A total of 1730 client-owned cats (722 AH, 1008 pHCM) from 21 countries.

Methods: Retrospective, multicenter, longitudinal, cohort study. Long-term health data were extracted by medical record review and owner/referring veterinarian interviews.

Results: Noncardiovascular death occurred in 534 (30.9%) of 1730 cats observed up to 15.2 years. Proportion of noncardiovascular death did not differ significantly between cats that at study enrollment were AH or had pHCM ($P = .48$). Cancer, chronic kidney disease, and conditions characterized by chronic weight-loss-vomiting-diarrhea-anorexia were the most frequently recorded noncardiovascular causes of death. Incidence rates/risk of noncardiac death increased with age in AH and pHCM. All-cause death proportions were greater in pHCM than AH (65% versus 40%, respectively; $P < .001$) because of higher cardiovascular mortality in pHCM cats. Comparing AH with pHCM, median survival (study entry to noncardiovascular death) did not differ (AH, 9.8 years; pHCM, 8.6 years; $P = .10$), but all-cause survival was significantly shorter in pHCM ($P = .0001$).

Conclusions and Clinical Importance: All-cause mortality was significantly greater in pHCM cats due to disease burden contributed by increased cardiovascular death superimposed upon noncardiovascular death.

KEYWORDS

cancer, chronic kidney disease, epidemiology, mortality, survival

1 | INTRODUCTION

Contemporary pet ownership surveys demonstrate substantial growth in feline pet populations. In the United States, there were approximately 74 million pet cats in 2012 (AVMA, US Pet Ownership & Demographics Sourcebook, 2012), and 94.2 million estimated for the 2017-2018 time period (2017-2018 APPA National Pet Owners Survey, http://americanpetproducts.org/pubs_survey.asp). Nevertheless, little has been published about long-term health outcomes of domestic cats, constraining development of effective health-monitoring strategies.

Most studies derive from veterinary insurance reports,[1-5] cemetery[6] and necropsy records,[7] surveys,[8-10] clinical registries,[11] national research databases,[12] health screening, and [13] medical record reviews from primary[14,15] and tertiary care[16] practices. Information from these sources is generally limited to prevalence data, that is, the percentage

of deaths due to a disease or condition identified at a point in time. However, insights regarding incidence, that is, the rate of new conditions arising in populations over time, are scarce; risk and survival comparisons for preclinical cohorts are largely unreported; and population effects related to age and cause-specific mortality remain uncertain.

The REVEAL study reported cardiovascular morbidity and survival in 1730 apparently healthy cats (AH) and cats with preclinical hypertrophic cardiomyopathy (pHCM).[17] To further our understanding of feline longevity, the present study aimed to identify the epidemiology of noncardiovascular and all-cause death and assess its overall impact on health in the same population. Specific objectives were to determine from medical records, the major causes of death, contrast incidence rates, risk, and survival characteristics, and compare these observations between susceptible populations and age groups over a prolonged period of time.

2 | MATERIALS AND METHODS

2.1 | Study design

Data were derived from an analysis of medical and demographic data collected for the REVEAL Study[17] project. Ethical review committee approval was obtained where required.

2.2 | Cats

Analysis included 1730 cats: 722 AH and 1008 pHCM (430 non-obstructive hypertrophic cardiomyopathy [HCM] and 578 obstructive hypertrophic cardiomyopathy [HOCM]).[17] Enrolled cats had normal physical examination except for the presence of heart murmurs in some cats. No other known serious illness or medical history abnormalities were detected. All had echocardiographic examinations performed at the time of study entry. The study cohort of AH received echocardiographic examinations for preanesthetic workups, to evaluate cardiac status when heart murmurs were detected, as part of case recruitment of AH without significant heart disease for the present study, and for breed screening in certain pedigrees.

2.2.1 | Inclusion criteria

Each investigator had a searchable echocardiographic and medical record database permitting detailed review and long-term health follow-up. Medical records were examined for cats diagnosed with either HCM or HOCM, and AH without cardiomyopathy, whose health outcomes could be ascertained for at least 5 years after the date of study entry. Archived echocardiographic images were reviewed to confirm diagnosis. Study entry was recorded as the date when echocardiographic examination was first performed.[17]

2.2.2 | Exclusion criteria

Any of the following conditions diagnosed at or before study entry resulted in study exclusion: congestive heart failure; arterial thromboembolism; syncope; heartworm disease; arterial hypertension (systolic arterial blood pressure ≥180 mm Hg); hyperthyroidism; anemia; chronic kidney disease (CKD), defined as any combination of serum creatinine concentration above laboratory reference interval, urine concentrating ability deemed to be inadequate or isosthenuria, proteinuria, and small, irregular kidneys; cardiomyopathy other than pHCM; congenital heart disease; cancer; any systemic, endocrine, hepatobiliary, pancreatic, or chronic gastrointestinal disease; and medical or surgical condition judged capable of limiting life expectancy.

2.3 | Study sites

Investigators participated from 50 veterinary centers in 21 countries.[17]

2.4 | Echocardiography

Cardiac diagnoses were confirmed from archived echocardiograms. Left ventricular (LV) hypertrophy represented end-diastolic LV free wall and or interventricular wall thickness ≥6 mm.[18] Hypertrophic obstructive cardiomyopathy was defined as LV hypertrophy with systolic anterior motion of the mitral valve, diffuse LV outflow tract turbulence, and peak systolic outflow velocity ≥2.5 m/s, whereas HCM represented hypertrophic cardiomyopathy without LV outflow tract obstruction.

2.5 | Data collection and outcomes assessment

Medical records where the first echocardiographic examination was performed between November 2001 and January 2011 were reviewed to

TABLE 1 Recorded deaths in cats that at study entry were diagnosed as apparently healthy or with preclinical HCM/HOCM

| Cause of death | Apparently healthy cats n = 722 | HCM n = 430 | HOCM n = 578 | HCM/HOCM n = 1008 |
	Number of events (%)	Number of events (%)	Number of events (%)	Number of events (%)
Cause-specific mortality				
Cancer	105 (14.5)	52 (12.1)	51 (8.8)	103 (10.2)
Chronic kidney disease	46 (6.4)	41 (9.5)	35 (6.1)	76 (7.5)
Chronic weight loss-vomiting-diarrhea-anorexia	32 (4.4)	24 (5.6)	26 (4.5)	50 (5.0)
Other diseases*	47 (6.5)	42 (9.8)	33 (5.7)	75 (7.4)
Unknown causes	49 (6.8)	25 (5.8)	43 (7.4)	68 (6.7)
Overall mortality				
Noncardiovascular causes	230 (31.9)	159 (37.0)	145 (25.1)	304 (30.2)
Cardiovascular causes	7 (1.0)	115 (26.7)	166 (28.7)	281 (27.9)
All causes**	286 (39.6)	299 (69.5)	354 (61.2)	653 (64.8)

Note: Data are arranged by the cause of death.

Abbreviations: HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy.

*Death related to anesthesia, respiratory diseases, central nervous system diseases, hepatobiliary diseases, toxicoses, endocrine diseases, trauma.

**Includes all cardiovascular, noncardiovascular, and unknown causes of death.

TABLE 2 Demographic characteristics (age, body weight, sex) for feline populations that were diagnosed at study entry as apparently healthy or preclinical HCM/HOCM

Study populations	Apparently healthy cats (n = 722)				HCM/HOCM (n = 1008)				P value
	Age, median (IQR), years	Body weight, median (IQR), kg	Sex M	Sex F	Age, median (IQR), years	Body weight, median (IQR), kg	Sex M	Sex F	Apparently healthy versus HCM/HOCM cats
Overall mortality									
Noncardiovascular	9.0 (5.2-12.6)	4.2 (3.4-5.1)	109	121	9.8 (6.0-12.2)	5.0 (4.0-5.9)	210	94	.48 (age) <0.0001 (body weight)
Cardiovascular	10 (6.8-11.0)	4.8 (3.9-7.2)	5	2	6.4 (3.0-9.6)	5.0 (4.2-6.1)	214	67	.03 (age) .83 (body weight)
All causes[b]	9.0 (5.0-12.2)	4.3 (3.5-5.3)	138	148	8.0 (4.0-11.0)	5.0 (4.1-6.0)	475	178	.006 (age) <.0001 (body weight)
Cause-specific mortality									
Cancer	10.5 (7.0-13.7)	4.6 (3.9-5.7)	53	52	9.0 (6.0-12.6)	4.9 (4.1-5.9)	66	37	.09 (age) .07 (body weight)
Chronic kidney disease	11.8 (7.0-14.0)	3.9 (3.2-4.9)	18	28	11.0 (8.2-14.0)	4.5 (3.8-5.5)	54	22	.87 (age) .03 (body weight)
Chronic weight loss-vomiting-diarrhea-anorexia	6.0 (3.6-11.0)	3.9 (3.2-4.7)	19	13	10.0 (5.4-11.8)	5.3 (4.3-6.1)	36	14	.02 (age) <.0001 (body weight)
Other noncardiovascular diseases[a]	6.5 (2.0-10.3)	4.0 (3.2-4.6)	19	28	9.7 (4.0-12.0)	4.1 (4.5-5.6)	54	21	0.02 (age) <0.0001 (body weight)
Unknown causes	9.0 (3.0-12.0)	4.5 (3.9-6.0)	24	25	8.0 (4.0-11.5)	5.2 (4.2-6.4)	50	18	.18 (age) .80 (body weight)

Note: Data are arranged by cause of death.

Abbreviations: HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy; IQR, interquartile range.

[a]Death related to anesthesia, respiratory diseases, central nervous system diseases, hepatobiliary diseases, toxicoses, endocrine diseases, trauma.

[b]Includes all cardiovascular, noncardiovascular, and unknown causes of death.

TABLE 3 Comparison of incidence rates of cause-specific death events per 1000 cat-years

Age	Population cohorts	Non-cardiovascular	Cardiovascular	All causes*	Cancer	Chronic kidney disease	Chronic weight loss-vomiting-diarrhea-anorexia	Other causes**	Unknown causes
Total population	Apparently healthy	60.9	1.9	75.4	27.8	12.7	8.7	11.1	12.7
	HCM/HOCM	68.6	63.4	147.4	23.2	17.8	11.5	12.2	15.3
Age quartile 1 (<2.5 years)	Apparently healthy	18.3	0	24.8	4.6	0	5.2	7.8	6.5
	HCM/HOCM	19.4	57.1	87.7	8.2	2.0	2.0	3.1	11.2
Age quartile 2 (2.5-5.6 years)	Apparently healthy	39.3	1.12	47.2	15.7	6.7	9.0	7.9	6.7
	HCM/HOCM	39.5	57.7	110.2	11.4	6.8	8.4	8.4	12.9
Age quartile 3 (>5.6-10 years)	Apparently healthy	80.4	4.7	101.7	34.3	18.9	10.6	13.0	16.6
	HCM/HOCM	69.7	72.7	153.4	29.4	19.1	11.7	10.3	11
Age quartile 4 (>10 years)	Apparently healthy	193.6	3.9	232.8	107.3	50.9	15.6	23.5	35.2
	HCM/HOCM	178.5	64.7	275.6	51.8	54.3	28.5	34.9	33.7

Note: Feline populations are defined by age quartile at the time of study entry when they were diagnosed as apparently healthy or preclinical HCM/HOCM. Data are arranged by cause of death.

Abbreviations: HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy.

*Includes all cardiovascular, noncardiovascular, and unknown causes of death.

**Death related to anesthesia, respiratory diseases, central nervous system diseases, hepatobiliary diseases, toxicoses, endocrine diseases, trauma.


FIGURE 1 Comparison of cardiovascular, noncardiovascular, and all-cause mortality rates per 1000 cat-years recorded over the study duration for 1730 cats. Clinical status was designated at study entry for 722 apparently healthy cats or preclinical hypertrophic (HCM) and hypertrophic obstructive (HOCM) cardiomyopathy (HCM/HOCM, n = 1008)


FIGURE 2 Mortality rates per 1000 cat-years for noncardiovascular (upper graph) and all-cause (lower graph) death compared by age quartile (Q) at the time of study entry when cats were diagnosed as apparently healthy cats (AH, n = 722) or preclinical hypertrophic (HCM) and hypertrophic obstructive (HOCM) cardiomyopathy (n = 1008)


FIGURE 3 Risk of noncardiovascular death recorded at 1, 2.5, 5, 7.5, and 10-year intervals after study entry in 1730 cats which, at the time of study entry, were diagnosed as apparently healthy cats (AH, n = 722) or preclinical hypertrophic (HCM) and hypertrophic obstructive (HOCM) cardiomyopathy (HCM/HOCM, n = 1008)

identify recorded death or permitted at least 5 years of follow-up. Data collection extended to January 2016. Pertinent demographic and survival information was recorded. Serum thyroxine and creatinine concentrations and systolic arterial blood pressure results closest to the date of

TABLE 4 Risk of mortality

		Noncardiovascular death		All-cause death*		Cancer death		Chronic kidney disease death		Chronic weight loss-vomiting-diarrhea-anorexia death		Other causes of death**	
		Population remaining at risk	Affected	Population remaining at risk	Affected	Population remaining at risk	Affected	Population remaining at risk	Affected	Population remaining at risk	Affected	Population remaining at risk	Affected
1 year after study entry													
Full population	AH	94.5	5.5	94.2	5.8	97.2	2.8	99.4	0.6	99.3	0.7	98.3	1.7
	HCM/HOCM	94.5	5.5	87.1	12.9	98.0	2.0	99.3	0.7	99.3	0.7	98.3	1.7
Age quartile1	AH	98.4	1.6	98.4	1.6	100.0	0.0	100.0	0.0	99.6	0.4	98.8	1.2
	HCM/HOCM	97.9	2.1	92.1	7.9	99.5	0.5	99.5	0.5	100.0	0.0	98.9	1.1
Age quartile 2	AH	96.1	3.9	96.1	3.9	98.7	1.3	99.4	0.6	98.7	1.3	99.4	0.6
	HCM/HOCM	95.6	4.4	87.5	12.5	98.9	1.1	99.3	0.7	98.9	1.1	99.3	0.7
Age quartile 3	AH	94.0	6.0	93.5	6.5	96.4	3.6	100.0	0.0	99.4	0.6	98.2	1.8
	HCM/HOCM	96.5	3.5	89.2	10.8	98.1	1.9	100.0	0.0	99.7	0.3	99.4	0.6
Age quartile4	AH	86.4	13.6	85.7	14.3	91.8	8.2	98.0	2.0	99.3	0.7	96.6	3.4
	HCM/HOCM	88.0	12.0	79.8	20.2	95.7	4.3	98.3	1.7	98.7	1.3	95.3	4.7
2.5 years after study entry													
Full population	AH	86.6	13.4	84.1	15.9	94.0	6.0	97.9	2.1	97.8	2.2	96.8	3.2
	HCM/HOCM	89.8	10.2	74.2	25.8	96.3	3.7	98.3	1.7	98.2	1.8	97.5	2.5
Age quartile1	AH	96.8	3.2	95.2	4.8	99.2	0.8	100.0	0.0	99.2	0.8	98.4	1.6
	HCM/HOCM	96.8	3.2	84.1	15.9	98.9	1.1	99.5	0.5	100.0	0.0	98.9	1.1
Age quartile 2	AH	91.6	8.4	90.3	9.7	98.1	1.9	98.7	1.3	97.4	2.6	97.4	2.6
	HCM/HOCM	92.6	7.4	79.0	21.0	98.2	1.8	98.5	1.5	98.2	1.8	98.9	1.1
Age quartile 3	AH	83.9	16.1	81.0	19.0	92.9	7.1	98.2	1.8	97.6	2.4	95.8	4.2
	HCM/HOCM	93.0	7.0	76.1	23.9	97.1	2.9	99.0	1.0	98.7	1.3	98.4	1.6
Age quartile 4	AH	66.7	33.3	61.9	38.1	82.3	17.7	93.2	6.8	95.9	4.1	94.6	5.4
	HCM/HOCM	76.4	23.6	57.9	42.1	91.0	9.0	96.1	3.9	96.1	3.9	93.6	6.0
5 years after study entry													
Full population	AH	76.2	23.8	70.4	29.6	89.2	10.8	95.6	4.4	96.7	3.3	95.0	5.0
	HCM/HOCM	78.8	21.2	51.7	48.3	93.0	7.0	95.1	4.9	96.6	3.4	95.4	4.6
Age quartile1	AH	91.7	8.3	88.1	11.9	98.0	2.0	100.0	0.0	97.6	2.4	96.8	3.2
	HCM/HOCM	94.7	5.3	67.7	32.3	98.4	1.6	99.5	0.5	99.5	0.5	98.4	1.6
Age quartile 2	AH	87.1	12.9	85.2	14.8	96.1	3.9	98.7	1.3	96.8	3.2	95.5	4.5
	HCM/HOCM	87.5	12.5	62.1	37.9	97.1	2.9	97.8	2.2	97.4	2.6	97.1	2.9

(Continues)

TABLE 4 (Continued)

		Noncardiovascular death		All-cause death*		Cancer death		Chronic kidney disease death		Chronic weight loss-vomiting-diarrhea-anorexia death		Other causes of death**	
		Population remaining at risk	Affected	Population remaining at risk	Affected	Population remaining at risk	Affected	Population remaining at risk	Affected	Population remaining at risk	Affected	Population remaining at risk	Affected
Age quartile 3	AH	71.4	28.6	63.7	36.3	86.3	13.7	95.2	4.8	96.4	3.6	94.6	5.4
	HCM/HOCM	80.9	19.1	51.0	49.0	92.0	8.0	95.9	4.1	97.1	2.9	96.2	3.8
Age quartile 4	AH	43.5	56.5	32.0	68.0	70.1	29.9	85.0	15.0	95.2	4.8	91.8	8.2
	HCM/HOCM	52.8	47.2	27.5	72.5	85.0	15.0	87.6	12.4	92.7	7.3	90.1	9.9
7.5 years after study entry													
Full population	AH	70.2	29.8	62.7	37.3	86.1	13.9	93.9	6.1	95.7	4.3	94.6	5.4
	HCM/HOCM	71.9	28.1	38.4	61.6	90.8	9.2	92.8	7.2	95.2	4.8	94.7	5.3
Age quartile1	AH	90.5	9.5	86.5	13.5	97.6	2.4	100.0	0.0	97.2	2.8	96.4	3.6
	HCM/HOCM	93.1	6.9	59.3	40.7	97.9	2.1	99.5	0.5	99.5	0.5	98.4	1.6
Age quartile 2	AH	80.6	19.4	76.1	23.9	92.3	7.7	97.4	2.6	95.5	4.5	95.5	4.5
	HCM/HOCM	83.5	16.5	50.4	49.6	95.2	4.8	97.4	2.6	96.3	3.7	96.3	3.7
Age quartile 3	AH	61.9	38.1	52.4	47.6	83.3	16.7	91.7	8.3	94.6	5.4	93.5	6.5
	HCM/HOCM	71.7	28.3	36.0	64.0	88.2	11.8	92.7	7.3	94.9	5.1	95.9	4.1
Age quartile 4	AH	34.0	66.0	19.7	80.3	63.3	36.7	82.3	17.7	94.6	5.4	91.8	8.2
	HCM/HOCM	41.6	58.4	10.7	89.3	83.3	16.7	82.0	18.0	91.0	9.0	88.4	11.6
10 years after study entry													
Full population	AH	68.6	31.4	60.8	39.1	85.5	14.5	93.4	6.6	95.6	4.4	94.3	5.7
	HCM/HOCM	70.2	29.8	35.8	64.1	89.9	10.1	92.4	7.6	95.0	5.0	94.6	5.4
Age quartile1	AH	89.3	10.7	85.3	14.6	97.2	2.8	100.0	0.0	97.2	2.8	95.6	4.4
	HCM/HOCM	90.5	9.5	55.6	44.3	95.8	4.2	98.9	1.1	99.5	0.5	98.4	1.6
Age quartile 2	AH	77.4	22.6	72.9	27.0	91.0	9.0	96.1	3.9	94.8	5.2	95.5	4.5
	HCM/HOCM	82.0	18.0	48.2	51.7	94.9	5.1	97.4	2.6	96.0	4.0	96.0	4.0
Age quartile 3	AH	60.7	39.3	50.0	49.9	82.7	17.3	91.1	8.9	94.6	5.4	93.5	6.5
	HCM/HOCM	69.7	30.3	33.4	66.5	87.3	12.7	91.7	8.3	94.9	5.1	95.9	4.1
Age quartile 4	AH	32.7	67.3	18.4	81.5	62.6	37.4	81.6	18.4	94.6	5.4	91.8	8.2
	HCM/HOCM	40.8	59.2	8.5	91.5	82.8	17.2	82.0	18.0	90.6	9.4	88.4	11.6

Note: For each cause of death listed in the top row, the percentage of affected population and remaining population still at risk is designated for each age quartile recorded at study entry. Risk is further detailed at 1-, 2.5-, 5-, 7.5-, and 10-year intervals after study entry.

Abbreviations: AH, apparently healthy cats; HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy.

*Includes all cardiovascular, noncardiovascular, and unknown causes of death.

**Death related to anesthesia, respiratory diseases, central nervous system diseases, hepatobiliary diseases, toxicoses, endocrine diseases, trauma.

diagnosis were examined but were not available for every case. Date of death was designated by natural death or euthanasia. Cause of death was inferred to be the predominant condition or disease which, based on all available information including medical history and physical examination findings, diagnostic imaging, clinical pathology, ancillary testing, histopathology from biopsy, and or necropsy, contributed most substantially. When cause or date of death was unavailable, or if medical and clinical circumstances associated with death were uncertain, referral veterinarians or the pet owners were interviewed, aided by a standardized medical questionnaire.[17] Cause of death was grouped into categories. Cancer death was supported by detection of a mass, masses, lymphadenopathy by physical examination or diagnostic imaging, or by confirmation from cytology, histology, or necropsy when performed. Supporting CKD death were history of polyuria and polydipsia, serum creatinine concentration exceeding laboratory reference interval, isosthenuria or inadequate urine concentrating ability, proteinuria, and small and irregular kidney size and shape by physical examination or abdominal ultrasound. Death was attributed to debilitation caused by 1 or more of the following: chronic weight loss, vomiting, diarrhea, and or anorexia (CWLVDA). Etiologies for CWLVDA mortality included exocrine pancreatic insufficiency and chronic, non-neoplastic gastrointestinal disease including inflammatory bowel disease, and without clinical evidence for cancer, endocrine, metabolic diseases, or known conditions that could have caused these signs. Cancer or CKD death was the designated cause of death if criteria for these diagnoses were met, even when malaise, weight loss, vomiting, or diarrhea was present. A noncardiovascular death category denoted as "other causes" was designated when death resulted from anesthetic complications, trauma, endocrine diseases including diabetes mellitus and hyperthyroidism, hepatobiliary diseases including hepatic lipidosis and cholangiohepatitis, central nervous system diseases, toxicoses, and respiratory system diseases. Death was classified as "unknown cause" when there was insufficient or conflicting information or overlapping comorbidities.

2.6 | Statistical analysis

Date of study entry was the time of echocardiographic examination and diagnosis. Data obtained at this time were evaluated in descriptive, baseline analyses, reported as mean and standard deviation for normally distributed variables, and median (interquartile range) for nonnormally distributed variables. Analysis of variance was used for between-group analyses, as error residuals were normally distributed based on visual inspection. Analyses for proportions of categorical variables were evaluated using chi-square or Fisher's exact test as appropriate. A generalized linear model was used to calculate incidence for the entire population and cohort level by age quartile expressed as rates per 1000 cat-years, as goodness of fit assumptions were met. Kaplan-Meier analysis was used to calculate proportion at-risk and compare noncardiovascular and all-cause survival within AH and HCM/HOCM cohorts. Survival time was further assessed at 1, 2.5, 5, 7.5, and 10-year intervals after study entry, and these specified time points dictated the percentage of patients at-risk as calculated by Kaplan-Meier, permitting a cross-sectional view of the respective time points. Additional analyses included stratification at age

quartile determined by age at study entry. Univariate time-to-event survival analyses were performed using Kaplan-Meier product limit estimates, where survival range was presented if median survival was not reached. Statistical differences between strata were determined by a log-rank test. Time-to-event survival time analyses represented time from study entry to end-date (death, date lost to follow-up, or remaining alive at study termination). Cases lost to follow-up or remaining alive were right-censored. Analyses were performed with SAS 9.4 (Cary, North Carolina). $P < .05$ was deemed significant.

3 | RESULTS

3.1 | Population characteristics at time of diagnosis

Study population demographic data were recently reported.[17] Briefly, median age of AH (4.9 years) was significantly younger than HCM (7.4 years; $P < .001$) and HOCM (5.7 years; $P = .01$) cohorts; HOCM were younger than HCM ($P < .001$) cohorts, and AH were also younger compared with the HCM/HOCM cohort (6.5 years; $P < .001$). Thirty-four breeds comprised the total population. Domestic Shorthair, Maine Coon cat, Persian, Domestic Longhair, and Norwegian Forest cat breeds were most prevalent.

3.2 | Overall mortality

Noncardiovascular death was recorded in 534 (30.9%) of 1730 cats. These comprised 230 (31.9%) of 722 AH, and 304 (30.2%) of 1008 HCM/HOCM (159 [37.0%] of 430 HCM and 145 [25.1%] of 578 HOCM; Table 1). Comparing AH with HCM/HOCM cats, there was no significant difference between the proportion of noncardiovascular


FIGURE 4 Survival analysis of 1730 cats that at study entry were diagnosed as apparently healthy (n = 722) or with preclinical HCM/HOCM (n = 1008). Percentage of cats that have not experienced death (y-axis) is plotted against time from study entry to time of noncardiovascular death (x-axis). Survival statistics include median and range (smallest and largest value): Apparently healthy cats, 9.8 years, 6 days-14.1 years; HCM/HOCM cats, 8.6 years, 2 days-15.2 years ($P = .10$). HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy

FIGURE 5 Survival analysis of 1730 cats that at study entry were diagnosed as apparently healthy (n = 722) or with preclinical HCM/HOCM (n = 1008). Percentage of cats that have not experienced death (y-axis) is plotted against time from study entry to time to all-cause death (x-axis). Survival statistics include median and range (smallest and largest value): Apparently healthy cats, 8.3 years, 6 days-14.1 years; HCM/HOCM cats, 5.1 years, 2 days-15.2 years (P = .0001). HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy

mortality (P = .48). Cancer, CKD, and CWLVDA were the most commonly recorded causes of noncardiovascular death. Demographic characteristics were compared for cardiovascular and noncardiovascular mortalities (Tables 1 and 2). Approximate male:female ratio for AH and HCM/HOCM cohorts were for cancer, 1:1, 1.8:1; CKD, 0.6:1, 2.5:1; and CWLVDA, 1.5:1, 2.6:1, respectively).

3.2.1 | Incidence

Mortality rates per 1000 cat-years were compared between cohorts defined by age quartile at the time of study entry and arranged by cause of death (Table 3). Noncardiovascular mortality was similar between AH and HCM/HOCM cats; however, all-cause mortality was substantially higher in HCM/HOCM compared to AH due to cardiovascular death, which occurred frequently in HCM/HOCM cats but rarely in AH (Figure 1). Overall, noncardiovascular and all-cause mortality rates were lowest in the first 2 age quartiles and increased with age (Table 3, Figure 2). Specifically, incidence rates for noncardiovascular death in AH were slightly more than twice higher in both the second compared with the first age quartile and in the third compared with the second quartile, and 2.4 times higher in the fourth compared with the third age quartile; in HCM/HOCM cats, noncardiovascular mortality was 2 times higher in the second compared with the first quartile, 1.8 times higher in the third compared with the second quartile, and 2.6 times higher in the fourth compared with the third quartile. For cause-specific mortality rates in AH, cancer death was 23.3 times higher in cats >10 years than in cats <2.5 years old; CKD death was 51 times higher in cats >10 than for cats <2.5 years; and CWLVDA death was 3 times higher in cats >10 than <2.5 years. In HCM/HOCM cats, cancer, CKD, and CWLVDA death rates also increased with age. Comparing their mortality rates between cats older than 10 years with cats younger than 2.5 years,


FIGURE 6 Survival analysis of 1730 cats stratified by age quartile (Q) at study entry when diagnosed as apparently healthy (n = 722; A) or with preclinical HCM/HOCM (n = 1008; B), and that died over time from noncardiovascular causes. Percentage of cats that have not experienced death (y-axis) is plotted against time from study entry to time to noncardiovascular death (x-axis). A, Q1: median not achieved, range 46 days-14.1 years; Q2; median 8.6 years, range 15 days-11.0 years; Q3: median 7.3 years, interquartile range (IQR) 3.8-13.6 years; Q4: median 3.4 years, IQR 2.2-6.9 years. Pairwise comparisons between age quartiles were P < .0001, except Q1 versus Q2 (P = .0009) and Q2 versus Q3 (P = .0007). B, All median, IQR. Q1: 9.8 years, 9.0-13.1 years; Q2: 11.1 years, 7.5-12.5 years; Q3: 8.0 years, 5.1-8.8 years; Q4: 4.2 years, 2.2-6.3 years. Pairwise comparisons between age quartiles were P < .0001, except Q1 versus Q2 (P = .006). HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy

cancer death was 6.3 times higher, CKD death was 27.2 times higher, and CWLVDA death was 14.3 times higher, respectively. In both AH and HCM/HOCM cohorts, CKD death incidence rate increased substantially with age, especially in the third and fourth age quartiles (Table 3).

3.2.2 | Risk

Risk of death due to noncardiovascular and all-cause mortalities increased variably at 1, 2.5, 5, 7.5, and 10-year intervals following

FIGURE 7 Survival analysis of 1730 cats stratified by age quartile (Q) at study entry when diagnosed as apparently healthy (n = 722; A) or with preclinical HCM/HOCM (n = 1008; B), and that died over time from all-cause death. Percentage of cats that have not experienced death (y-axis) is plotted against time from study entry to time to all-cause death (x-axis). A, Q1: Median not achieved, range 46 days-14.1 years; Q2: median 8.6 years, range 15 days-11.0 years; Q3: median 6.9 years, interquartile range (IQR) 3.3-13.6 years; Q4: median 3.1 years, IQR 2.0-5.5 years. Pairwise comparisons between age quartiles were $P < .0001$, except Q1 versus Q2 ($P = .002$). B, All median, IQR. Q1: 7.5 years, 4.1-9.8 years; Q2: 6.5 years, 3.1-11.1 years; Q3: 5.0 years, 2.7-8.0 years; Q4: 3.0 years, 1.3-5.2 years. Pairwise comparisons between age quartiles were $P < 0001$, except Q1 versus Q2 ($P = .10$) and Q2 versus Q3 ($P = .0003$). HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy

FIGURE 8 Survival analysis of 1730 cats that at study entry were diagnosed as apparently healthy (n = 722) or preclinical HCM/HOCM (n = 1008), and that died over time due to cancer, CKD, or CWLVDA. Percentage of cats that have not experienced death (y-axis) is plotted against time from study entry to time to cause-specific death (x-axis). Survival statistics include range (smallest and largest value); median survival was not achieved. A, Death from cancer. AH, 6 days-14.1 years; HCM/HOCM cats, 14 days-13.1 years ($P = .28$). B, Death from CKD. AH, 28 days-14.1 years; HCM/HOCM cats, 16 days-13.1 years ($P = .04$). C, Death from CWLVDA. AH 6 days-14.1 years; HCM/HOCM cats, 2 days-15.2 years ($P = .18$). HCM, nonobstructive hypertrophic cardiomyopathy; HOCM, obstructive hypertrophic cardiomyopathy; CKD, chronic kidney disease; CWLVDA, chronic weight-loss-vomiting-diarrhea-anorexia

study entry (Table 4, Figure 3). For noncardiovascular mortality, the largest risk increments were recorded at 2.5 years compared with 1 year, and 5 years compared with 2.5 years following study entry (in AH 2.4 and 1.8 times higher, respectively; in HCM/HOCM cats 1.9 and 2.1 times higher, respectively). For all-cause mortality, the largest risk increments were recorded at 2.5 years compared with 1 year and at 5 years compared with 2.5 years (in AH 2.7 and 1.9 times higher, respectively; in HCM/HOCM 2.0 and 1.9 times higher at each comparison, respectively). Noncardiovascular risk was 4.3 and 3.9 times

higher at 5 years compared with 1 year following study entry for AH and HCM/HOCM cats, respectively. In AH, risk of cancer, CKD, and CWLVDA death was 3.9, 7.3, and 4.7 times higher at 5 years compared with 1 year following study entry, respectively; risks for the

same mortalities in HCM/HOCM cats were 3.5, 7.0, and 4.9 times higher at 5 years compared with 1 year after study entry, respectively. The increment of risk for these mortalities was comparatively higher at 5 years compared with 10 years after study entry for AH and HCM/HOCM cats. Comparative risk of CKD death was greatest in cats that were in the fourth age quartile at study entry (Table 4).

3.3 | Survival analyses

Survival time from study entry to noncardiovascular death did not differ significantly in AH (median, 9.8 years; range, 6 days-14.1 years) compared with HCM/HOCM cats (median, 8.6 years; range, 2 days-15.2 years; P = .10; Figure 4). Survival times to all-cause death were significantly shorter in HCM/HOCM cats (median, 5.1 years; range, 2 days-15.2 years) compared to AH (median, 8.3 years; range, 6 days-14.1 years; P = .0001; Figure 5). Survival curves for AH and HCM/HOCM cats stratified by age quartile at time of study entry diverged markedly for noncardiovascular (Figure 6) and all-cause (Figure 7) death, most notably for the second and third, and the third and fourth age quartiles. This was largely caused by cancer and CKD deaths (Table 4). For example, at 2.5 years after study entry, risk of cancer death in AH was 7.1% in the third and 17.7% in the fourth age quartile. At 7.5 years after study entry, risk of cancer death was 16.7% in the third and 36.7% in the fourth age quartile.

Survival from study entry to recorded cancer death did not differ significantly between AH (median not achieved [NA]; range, 6 days-14.1 years) and HCM/HOCM cats (NA; range, 14 days-13.1 years; P = .28; Figure 8A). By contrast, survival to CKD death was significantly shorter in HCM/HOCM cats (NA; range, 16 days-13.1 years) compared with AH (median NA; 28 days-14.1 years; P = .04; Figure 8B). Survival to CWLVDA death did not differ significantly between AH (NA; range, 6 days-14.1 years) compared with HCM/HOCM cats (median NA, range, 2 days-15.2 years; P = .18; Figure 8C).

4 | DISCUSSION

We identified noncardiovascular causes of death and examined all-cause mortality, incidence rates, risk, and survival characteristics in 1730 cats. To the best of our knowledge, this represents the first long-term comparison of causes of death between populations that at study entry were initially healthy or had preclinical HCM/HOCM. Death from cancer, CKD and CWLVDA represented 75%-80% of noncardiovascular mortality in cats originating from around the world, confirming the major impact of these conditions on life expectancy.[1-6,8,11-13] These findings complement the epidemiology of cardiovascular mortality reported from the same population.[17] In the present study, all-cause mortality was significantly greater and survival duration was significantly shorter in HCM/HOCM cats compared to AH, due to cardiovascular death that was substantial in HCM/HOCM cats but rare in AH.

Cancer was the most frequently recorded cause of noncardiovascular death. Apparently healthy cats and HCM/HOCM cats with cancer death did not differ significantly for age at study entry or for survival time. In AH

compared with HCM/HOCM cats, the increment of cancer death risk was substantial by 5 years (1 in 9 and 1 in 14, respectively) compared with 1 year (1 in 36 and 1 in 50, respectively) after study entry. By comparison at 10 years after study entry, risk was 1 in 7 and 1 in 10, respectively. Population-based data describing epidemiology of feline neoplasia are scant. Direct comparison with our findings is problematic due to diverse study populations, disparate inclusion criteria, and dissimilar methods for disease estimation.[19-23] Lymphoma is the most commonly reported feline neoplasm[20] and most prevalent form of gastrointestinal cancer.[24,25] However, we did not attempt to document histological diagnoses in all cats whose deaths were attributed to cancer in our study.

Chronic kidney disease was the second most commonly recorded cause of noncardiovascular death. As with cancer, CKD death predominantly affected middle-aged and older cats. Similar to cancer, in both AH and HCM/HOCM cats, the increment of CKD death risk was greatest at 5 years (1 in 23 and 1 in 20, respectfully) compared with 1 year (1 in 167 and 1 in 143, respectively) after study entry. By comparison, CKD death risk was 1 in 15 and 1 in 13 at 10 years, after study entry, respectively. Neutered male compared with spayed female status was reported to be a CKD risk factor.[26] In our study, sex ratio with CKD death was approximately 1.6 to 1 female-to-male in AH and 2.5 to 1 male-to-female in HCM/HOCM cats. However, heart disease was excluded in AH, whereas HCM/HOCM is associated with strong male predilection, possibly explaining these differences.

Survival from study entry to CKD death was significantly shorter in HCM/HOCM cats compared with AH. Although age at study entry did not differ significantly between AH and HCM/HOCM cats with recorded CKD death, the HCM/HOCM cohort was significantly older than AH and might have introduced a population bias, because prevalence of CKD increases with age.[13,26-29] Consequently, we cannot resolve whether pHCM predisposed to acute kidney injury as a hypothesis for their shorter survival time to CKD death, compared with AH. This merits further study.

Death associated with CWLVDA was the third most commonly recorded cause of noncardiovascular death. Compared with cancer death, incidence rates were approximately one-third lower in AH and one-half lower in HCM/HOCM cats, respectively. Consistent with cancer and CKD death, the increment of risk for CWLVDA death in AH and HCM/HOCM cats was greatest at 5 years (approximately 1 in 30 and 1 in 29 respectively) compared with 1 year (1 in 143) after study entry. Middle-age predilection has been reported for feline inflammatory bowel disease, 1 of the most common feline enteropathies.[30,31] In our study, the cohort of AH with recorded CWLVDA death were middle-aged at the time of study entry.

How best to apply epidemiology to promote disease detection and improve feline health remains a long-standing topic of interest,[13,28,32-37] especially because current metrics to assess disease have limitations. Age categories are considerably subjective, as designated, for example, by middle-aged, adult, mature, senior, or geriatric labels that are commonly applied. Indeed, interpreting age-appropriate physical and physiologic aging changes may be ambiguous. Collectively, predicting risk based solely upon time from birth is indeterminate.[38-41] Nonetheless, increased health screening has been routinely advocated for "older" cats,

2584 | Journal of Veterinary Internal Medicine **ACVIM** Open Access American College of Veterinary Internal Medicine

FOX ET AL.

emphasizing medical history, physical examination, and laboratory testing as footings to detect illness.[28,32-36,42] Often, however, medical history and physical examination findings are vague or unremarkable. Furthermore, blood test variables might be unaffected, particularly in early disease stages and even when certain disease has progressed.[43] Laboratory reference intervals that reflect normal aging improves test acuity,[15] but available data are limited. Thus, screening clinical pathology test values frequently fall within normal reference intervals,[13] and normal findings might not reflect the state of health nor assure the absence of disease.

The present study reports survival characteristics, incidence rates, and mortality risk in feline populations that at study entry were apparently healthy or had pHCM. These methods afford a constructive approach to support healthcare planning, and our findings provide informative considerations for future screening programs. We prioritized analysis of incidence over prevalence in order to compare noncardiovascular, all-cause, and cause-specific mortality across age quartiles and between-study populations. Most feline reports emphasize prevalence,[1-13] which describes the total number of cases in a study population at a single time point, but is affected by disease duration and occurrence, and is not well suited for monitoring disease trends.[44] Our study revealed that cancer, CKD, and CWLVDA death were the major causes of noncardiovascular death. Although older cats had the highest noncardiovascular mortality event rates, substantial mortality was also recorded in the middle 2 age quartiles, ages not customarily targeted for enhanced wellness screening. We also observed that the greatest increment of risk for death caused by cancer, CKD, and CWLVDA occurred at 2.5 and 5 years compared with 1 year after study entry. The increment of risk for noncardiovascular death after study entry in AH and HCM/HOCM cats increased approximately 2.4 and 1.9 times at 2.5 years compared with 1 year, respectively, and increased further, by approximately 1.8 and 2.1 times at 5 years compared with 2.5 years after study entry, respectively. These findings might contribute to planning screening visits.

There were several important study limitations. As this was a retrospective study, it was not feasible to collect comprehensive test data, biopsy procedures, or necropsy results on every case, and we were not able to refine survival analyses according to histologic grading of cancer. Although exclusionary criteria were imposed to screen out cases with obvious clinical illness, some diseases may have been undetected. Attributing cause of death in cases associated with gastrointestinal signs of disease can be difficult. Indeed, well-recognized challenges have been reported, including shifting and controversial classification systems, evolving terminology, unsettled diagnostic criteria, and uncertain test accuracy.[30] Distinguishing between inflammatory bowel disease and lymphoma, the 2 principal diseases affecting the feline gastrointestinal system is especially problematic and comorbidities may exist.[45-52] Although cause of death was relegated to an "unknown category" whenever information was insufficient, misclassification of cause-specific death was possible. However, the broader categories of noncardiovascular and all-cause death still provide meaningful bases for comparing populations and age quartiles. Referral bias might have been present at some study sites. Moreover, some selection bias might have resulted because some AH were examined with echocardiography to assess a heart murmur for breeding examination or preanesthesia evaluation. It was not possible to assure that study populations represented endemic disease burdens in each geographic region. Thus, incidence rates might have been overrepresented or underrepresented at some sites. However, we are unaware of comprehensive survey data confirming geographic distribution of feline diseases. Our relatively large study population originating from varied geographical regions might have diminished these effects. We did not attempt to identify benefit or detriment of any drug treatment on the natural history of study populations or assess whether diet, genetic, or environmental factors influenced health and longevity[19,49,53] Moreover, we could not control for possible regional attitudes towards euthanasia that might have influenced survival. Finally, cardiac status was based on 1 initial echocardiographic examination at the point of study entry. Limitations related to these factors have been detailed.[17]

5 | CONCLUSIONS

Notwithstanding these limitations, our study contributes new epidemiologic information about noncardiovascular and all-cause mortality, including incidence rates, risk, and survival outcomes in cats that at study entry were apparently healthy or had pHCM. The most commonly recorded noncardiovascular causes of death were cancer, followed by CKD, and then conditions characterized by CWLVDA. Although life spans of AH and pHCM cats that died from noncardiovascular causes were similar, pHCM conferred a substantial health burden over-and-above the risk for noncardiovascular death. All-cause mortality was significantly greater in pHCM due to cardiovascular death which was common in this cohort but rare in AH.

Noncardiovascular death approximately doubled every successive age quartile in AH and pHCM cats. Moreover, the increment of risk of noncardiovascular death was highest at 2.5 years compared with 1 year after study entry and 5 years compared with 2.5 years after study entry, respectively, approximately doubling at each comparative time point. Furthermore, increment of noncardiovascular risk was approximately 4 times higher at 5 years than at 1 year after study entry. Comparatively, this increment was higher than the increment of risk recorded 10 years versus 5 years after study entry. Still, although noncardiovascular mortality increased with advancing age, it was also notably present in middle-aged populations, cohorts that are often underemphasized in contemporary health screening guidelines.

Collectively, these findings add new epidemiologic information that may assist veterinarians anticipate potential health conditions, contribute to the future development of health care guidelines, and aid long-term surveillance and wellness monitoring strategies.

CONFLICT OF INTEREST DECLARATION

OFF-LABEL ANTIMICROBIAL DECLARATION

Authors declare no off-label use of antimicrobials.

INSTITUTIONAL ANIMAL CARE AND USE COMMITTEE (IACUC) OR OTHER APPROVAL DECLARATION

Where required by participating author institutions for this retrospective study.

HUMAN ETHICS APPROVAL DECLARATION

Authors declare human ethics approval was not needed for this study.

ORCID

Philip R. Fox https://orcid.org/0000-0003-4089-0573

Bruce W. Keene https://orcid.org/0000-0002-4758-5654

Valérie Chetboul https://orcid.org/0000-0001-7891-1814

Gerhard Wess https://orcid.org/0000-0002-6634-8072

Jonathan A. Abbott https://orcid.org/0000-0001-6981-8968

Jens Häggström https://orcid.org/0000-0003-3402-023X

John E. Rush https://orcid.org/0000-0002-8277-8996

Pamela Ming-Show Lee https://orcid.org/0000-0001-6003-0496

SeungWoo Jung https://orcid.org/0000-0002-6313-3084

Alice Tamborini https://orcid.org/0000-0003-3589-203X

Mark A. Oyama https://orcid.org/0000-0002-5218-9226

REFERENCES

1. Inoue M, Hasegawa A, Sugiura K. Morbidity pattern by age, sex and breed in insured cats in Japan (2008-2013). *J Feline Med Surg*. 2016; 18:1013-1022.
2. Egenvall A, Nødtvedt A, Häggström J, et al. Mortality of life-insured Swedish cats during 1999-2006: age, breed, sex, and diagnosis. *J Vet Intern Med*. 2009;23:1175-1183.
3. Bonnett BN, Egenvall A. Age patterns of disease and death in insured Swedish dogs, cats, and horses. *J Comp Pathol*. 2010;142:S33-S38.
4. Öhlund M, Fall T, Ström Holst B, Hansson-Hamlin H, Bonnett B, Egenvall A. Incidence of diabetes mellitus in insured Swedish cats in relation to age, breed and sex. *J Vet Intern Med*. 2015;29:1342-1347.
5. McCann TM, Simpson KE, Shaw DJ, et al. Feline diabetes mellitus in the UK: the prevalence within an insured cat population and a questionnaire-based putative factor analysis. *J Feline Med Surg*. 2007; 9:289-299.
6. Hayashidani H, Omi Y, Ogawa M, Fukutomi K. Epidemiological studies on the expectation of life for cats computed from animal cemetery records. *Nihon Juigaku Zasshi*. 1989;51:905-908.
7. Olsen TF, Allen AL. Causes of sudden and unexpected death in cats: a 10 year retrospective study. *Can Vet J*. 2001;42:61-62.
8. Vapalahti K, Virtala AM, Joensuu TA, et al. Health and behavioural survey of over 8000 Finnish cats. *Front Vet Sci*. 2016;3:1-16.
9. New JC Jr, Kelch WJ, Hutchison JM, et al. Birth and death rate estimates of cats and dogs in U.S. households and related factors. *J Appl Anim Welf Sci*. 2004;7:229-241.
10. Comfort A. Maximum ages reached by domestic cats. *J Mammal*. 1956;37:118-119.
11. Vascellari M, Baioni E, Ru G, Carminato A, Mutinelli F. Animal tumour registry of two provinces in northern Italy: incidence of spontaneous tumours in dogs and cats. *BMC Vet Res*. 2009;5:39.
12. O'Neill DG, Church DB, McGreevy PD, et al. Prevalence of disorders recorded in cats attending primary-care veterinary practices in England. *Vet J*. 2014;202:286-291.
13. Paepe D, Verjans G, Duchateau L, Piron K, Ghys L, Daminet S. Routine health screening: findings in apparently healthy middle-aged and older cats. *J Feline Med Surg*. 2013;15:8-19.
14. Doria-Rose VP, Scarlett JM. Mortality rates and causes of death among emaciated cats. *J Am Vet Med Assoc*. 2000;216:347-351.
15. Lund EM, Armstrong PJ, Kirk CA, Kolar LM, Klausner JS. Health status and population characteristics of dogs and cats examined at private veterinary practices in the United States. *J Am Vet Med Assoc*. 1999; 214:1336-1341.
16. Hamilton JB, Hamilton RS, Mestler GE. Duration of life and causes of death in domestic cats: influence of sex, gonadectomy, and inbreeding. *J Gerontol*. 1969;24:427-437.
17. Fox PR, Keene BW, Lamb K, et al. International collaborative study to assess cardiovascular risk and evaluate long-term health in cats with preclinical hypertrophic cardiomyopathy and apparently healthy cats: the REVEAL study. *J Vet Intern Med*. 2018;32:930-943.
18. Fox PR, Liu SK, Maron BJ. Echocardiographic assessment of spontaneously occurring feline hypertrophic cardiomyopathy. An animal model of human disease. *Circulation*. 1995;92:2645-2651.
19. Cupp CJ, Jean-Philippe C, Kerr WW, et al. Effect of nutritional interventions on longevity of senior cats. *Int J Appl Res Vet Med*. 2007;5: 133-149.
20. MacVean DW, Monlux AW, Anderson PS Jr, et al. Frequency of canine and feline tumors in a defined population. *Vet Pathol*. 1978;15: 700-715.
21. Brønden LB, Flagstad A, Kristensen AT. Veterinary cancer registries in companion animal cancer: a review. *Vet Comp Oncol*. 2007;5: 133-144.
22. Graf R, Grüntzig K, Boo G, et al. Swiss feline cancer registry 1965-2008: the influence of sex, breed and age on tumour types and tumour locations. *J Comp Pathol*. 2016;154:195-210.
23. Graf R, Grüntzig K, Hässig M, et al. Swiss feline cancer registry: a retrospective study of the occurrence of tumours in cats in Switzerland from 1965 to 2008. *J Comp Pathol*. 2015;153:266-277.
24. Gieger T. Alimentary lymphoma in cats and dogs. *Vet Clin North Am Small Anim Pract*. 2011;41:419-432.
25. Malik R, Gabor LJ, Canfield PJ. Lymphoma in Australian cats—lessons for Europe? *J Feline Med Surg*. 2003;5:147-150.
26. Greene JP, Lefebvre SL, Wang M, Yang M, Lund EM, Polzin DJ. Risk factors associated with the development of chronic kidney disease in cats evaluated at primary care veterinary hospitals. *J Am Vet Med Assoc*. 2014;244:320-327.
27. Bartges JW. Chronic kidney disease in dogs and cats. *Vet Clin North Am Small Anim Pract*. 2012;42:669-692.
28. Paepe D, Daminet S. Feline CKD: diagnosis, staging and screening—what is recommended? *J Feline Med Surg*. 2013;15(Suppl 1):15-27.
29. DiBartola SP, Rutgers HC, Zack PM, Tarr MJ. Clinicopathologic findings associated with chronic renal disease in cats: 74 cases (1973–1984). *J Am Vet Med Assoc*. 1987;190:1196-1202.
30. Jergens AE. Feline idiopathic inflammatory bowel disease: what we know and what remains to be unraveled. *J Feline Med Surg*. 2012;14: 445-458.
31. Sabattini S, Bottero E, Turba ME, Vicchi F, Bo S, Bettini G. Differentiating feline inflammatory bowel disease from alimentary lymphoma in duodenal endoscopic biopsies. *J Small Anim Pract*. 2016; 57:396-401.
32. Pittari J, Rodan I, Beekman G, et al. American association of feline practitioners. Senior care guidelines. *J Feline Med Surg*. 2009;11: 763-778.

33. Hoyumpa Vogt A, Rodan I, Brown M, et al. AAFP-AAHA: feline life stage guidelines. *J Feline Med Surg*. 2010;12:43-54.

34. American Animal Hospital Association—American Veterinary Medical Association Preventive Healthcare Guidelines Task Force. Development of new canine and feline preventive healthcare guidelines designed to improve pet health. *J Am Vet Med Assoc*. 2011;239:625-629.

35. Vogt AH, Rodan I, Brown M, et al. AAFP-AAHA: Feline life stage guidelines. *J Anim Hosp Assoc*. 2010;46:70-85.

36. Fortney WD. Implementing a successful senior/geriatric health care program for veterinarians, veterinary technicians, and office managers. *Vet Clin North Am Small Anim Pract*. 2012;42:823-834.

37. Belshaw Z, Robinson NJ, Dean RS, Brennan ML. Owners and veterinary surgeons in the United Kingdom disagree about what should happen during a small animal vaccination consultation. *Vet Sci*. 2018;5:1-12.

38. Day MJ. Ageing, immunosenescence and inflammageing in the dog and cat. *J Comp Pathol*. 2010;142 Suppl 1:S60-S609.

39. Seward JB. Physiological aging: window of opportunity? *J Am Coll Cardiol Cardiovasc Imaging*. 2011;4:243-245.

40. Bellows J, Center S, Daristotle L, et al. Aging in cats: common physical and functional changes. *J Feline Med Surg*. 2016;18:533-550.

41. Bellows J, Center S, Daristotle L, et al. Evaluating aging in cats: how to determine what is healthy and what is disease. *J Feline Med Surg*. 2016;18:551-570.

42. Metzger FL, Rebar AH. Clinical pathology interpretation in geriatric veterinary patients. *Vet Clin North Am Small Anim Pract*. 2012;42:615-629.

43. Dell'Osa D, Jaensch S. Prevalence of clinicopathological changes in healthy middle-aged dogs and cats presenting to veterinary practices for routine procedures. *Aust Vet J*. 2016;94:317-323.

44. Ward MW. Estimating disease prevalence and incidence using administrative data: some assembly required. *J Rheumatol*. 2013;40:1241-1243.

45. Jugan MC, August JR. Serum cobalamin concentrations and small intestinal ultrasound changes in 75 cats with clinical signs of gastrointestinal disease: a retrospective study. *J Feline Med Surg*. 2017;19:48-56.

46. Bertal M, Norman Carmel E, Diana A, Desquilbet L, Specchi S, Pey P. Association between ultrasonographic appearance of splenic parenchyma and cytology in cats. *J Feline Med Surg*. 2018;20:23-29.

47. Marolf AJ, Bachand AM, Sharber J, Twedt DC. Comparison of endoscopy and sonography findings in dogs and cats with histologically confirmed gastric neoplasia. *J Small Anim Pract*. 2015;56:339-344.

48. Daniaux LA, Laurenson MP, Marks SL, et al. Ultrasonographic thickening of the muscularis propria in feline small intestinal small cell T-cell lymphoma and inflammatory bowel disease. *J Feline Med Surg*. 2014;16:89-98.

49. Moore PF, Woo JC, Vernau W, Kosten S, Graham PS. Characterization of feline T cell receptor gamma (TCRG) variable region genes for the molecular diagnosis of feline intestinal T cell lymphoma. *Vet Immunol Immunopathol*. 2005;106:167-178.

50. Kleinschmidt S, Harder J, Nolte I, Marsilio S, Hewicker-Trautwein M. Chronic inflammatory and non-inflammatory diseases of the gastrointestinal tract in cats: diagnostic advantages of full-thickness intestinal and extraintestinal biopsies. *J Feline Med Surg*. 2010;12:97-103.

51. Kiupel M, Smedley RC, Pfent C, et al. Diagnostic algorithm to differentiate lymphoma from inflammation in feline small intestinal biopsy samples. *Vet Pathol*. 2011;48:212-222.

52. Gaschen L. Ultrasonography of small intestinal inflammatory and neoplastic diseases in dogs and cats. *Vet Clin North Am Small Anim Pract*. 2011;41:329-344.

53. Cupp CJ, Kerr WW, Jean-Philippe C, et al. The role of nutritional interventions in the longevity and maintenance of long-term health in aging cats. *Int J Appl Res Vet Med*. 2008;6:69-81.